ArticleJournal of clinical medicine2020
Effect of Evolocumab on Vulnerable Coronary Plaques: A Serial Coronary Computed Tomography Angiography Study.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Territorial heterogeneity of atherosclerosis and vascular calcification.Nature cardiovascular research · 2026Review
- PCSK9 inhibition after heart transplantation: how low does low-density lipoprotein cholesterol need to go for cardiac allograft vasculopathy prevention?Journal of thoracic disease · 2026Article
- Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events.Current cardiology reports · 2025Review
- Increased high-risk plaque burden in type 2 diabetes: a 10-year follow-up study.Cardiovascular diabetology · 2025Article
- Efficacy and Safety of Evolocumab in Improving Low-Density Lipoprotein Cholesterol (LDL-C) Levels in a Japanese Population - Systematic Review and Meta-Analysis.Circulation reports · 2025Article
- Inflammation in atherosclerosis: a Big Idea that has underperformed so far.Current opinion in lipidology · 2025Review
- Plasma proteomics improves prediction of coronary plaque progression.European heart journal. Cardiovascular Imaging · 2025Article
- Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque.Journal of clinical medicine · 2025Review
- PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring?Current atherosclerosis reports · 2024Review
- Optical Coherence Tomography in Myocardial Infarction Management: Enhancing Precision in Percutaneous Coronary Intervention.Journal of clinical medicine · 2024Review
- Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography.Cardiovascular diabetology · 2024Observational
- Management of Coronary Vulnerable Plaque With Medical Therapy or Local Preventive Percutaneous Coronary Intervention.JACC. Asia · 2024Review
- Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography.European heart journal · 2024Review
- Computed tomographic angiography measures of coronary plaque in clinical trials:Frontiers in cardiovascular medicine · 2024Review
- New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.International journal of molecular sciences · 2023Review
- Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statementAmerican journal of preventive cardiology · 2022Article
- Prognostic Value of Serial Coronary CT Angiography in Atherosclerotic Plaque Modification: What have we learnt?Current cardiovascular imaging reports · 2022Article
- Clinical Course of Optical Coherence Tomography-Detected Lipid-Rich Coronary Plaque After Optimal Medical Therapy.Circulation reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects of evolocumab on vulnerable coronary plaques and factors associated with the change in stability and size of plaques in patients taking statins. Vulnerable coronary plaques were defined using coronary computed tomography (CT) angiography as having a density of <50 HU within the region of interest and a remodeling index ≥1.1. The changes in minimum CT density, remodeling index, and percent stenosis of vulnerable coronary plaques after six months of evolocumab administration were retrospectively analyzed in 136 vulnerable coronary plaques from 98 patients (68 men and 30 women; mean age: 72.9 ± 8.7 years) treated with a statin. The administration of evolocumab significantly increased the minimum CT density (39.1 ± 8.1 HU to 84.9 ± 31.4 HU,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.